Role of Combination Therapy in Women With Refractory Overactive Bladder
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 29, 2024
Trial Information
Current as of February 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The study will be a prospective double-blinded randomized control trial to examine the effect of administering vibegron versus placebo in conjunction with intradetrusor onabotulinumtoxinA injections for the management of refractory OAB. Patients who present to the University of Alabama at Birmingham urogynecology practice with refractory OAB undergoing the standard 100U intradetrusor onabotulinumtoxinA will be offered enrollment to either the onabotulinumtoxinA plus vibegron or the onabotulinumtoxinA plus placebo groups. Prior to onabotulinumtoxinA injections, patients' baseline demographic...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Women undergoing intradetrusor botulinum injections for refractory OAB
- • 2. Age 18 years old or greater
- • 3. Fluency and literacy in English
- • 4. Capacity to provide consent
- Exclusion Criteria:
- • 1. Allergy to Vibegron
- • 2. Currently pregnant or planning to become pregnant
- • 3. Breastfeeding
- • 4. Current digoxin use
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0